Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 3

Results For "Glenmark"

141 News Found

Briefs: Morepen Laboratories, Glenmark Life Sciences, Gland Pharma and Shalby
News | January 16, 2025

Briefs: Morepen Laboratories, Glenmark Life Sciences, Gland Pharma and Shalby

Morepen Laboratories approves hiving off of medical devices business


Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL
News | December 17, 2024

Glenmark USA launches Lacosamide Oral Solution, 10 mg/mL

According to IQVIATM sales data for the 12-month period ending October 2024, the Vimpat Oral Solution, 10 mg/mL market achieved annual sales of approximately $57.0 million


Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody
Diagnostic Center | December 10, 2024

Ichnos Glenmark Innovation presents first clinical data from Phase 1 study of Trispecific TREAT antibody

Showing High Overall Response Rate (ORR) with durable responses and favorable safety profile in patients with heavily pretreated multiple myeloma


Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP, 0.004%
News | November 28, 2024

Glenmark Pharmaceuticals USA launches Travoprost Ophthalmic Solution USP, 0.004%

Glenmark's Travoprost Ophthalmic Solution USP, 0.004% is bioequivalent and therapeutically equivalent to the reference listed drug, Travatan Z Ophthalmic Solution USP, 0.004% of Sandoz


Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting
Diagnostic Center | November 07, 2024

Ichnos Glenmark Innovation to present Phase 1 study of Trispecific ISB 2001 in r/rMM at ASH Annual Meeting

ISB 2001 demonstrated a favorable safety and tolerability profile, and an overall response rate (ORR) of 75% in r/r MM


Glenmark Life Sciences posts Q2 FY25 net profit at Rs. 95.31 Cr
News | October 26, 2024

Glenmark Life Sciences posts Q2 FY25 net profit at Rs. 95.31 Cr

Glenmark Life Sciences has reported total income of Rs. 515.41 crores during the period ended September 30, 2024


Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals
Drug Approval | September 22, 2024

Briefs: Biocon, Aarti Drugs and Glenmark Pharmaceuticals

Glenmark Pharmaceuticals Limited has informed that the USFDA has issued Form 483 with zero observations


Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP
News | August 19, 2024

Glenmark Therapeutics launches Olopatadine Hydrochloride Ophthalmic Solution USP

This addition highlights our commitment to meeting market needs and providing high-quality over the-counter solutions for our customers


Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr
News | August 15, 2024

Glenmark Pharma reports Q1 FY25 consolidated PAT at Rs. 340.2 Cr

India Business grew by 11.9% YoY to Rs. 1196.2 crore


Glenmark Life Sciences posts Q1 FY25 PAT at Rs. 111.48 Cr
News | July 26, 2024

Glenmark Life Sciences posts Q1 FY25 PAT at Rs. 111.48 Cr

Glenmark Life Sciences has reported total income of Rs. 594.109 crores during the period ended June 30, 2024